

Published bi-monthly by:



806328 Sideroad 25
Meaford, Ontario
N4L 1W7
Canada

Phone: 519-578-9897
www.multi-med.com

Current Oncology is indexed/covered in MEDLINE, PubMed, EMBASE, SCOPUS, CrossRef, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in *Current Oncology*, the full text of each article is available immediately and archived in PubMed Central (PMC).

Peer Review Policy: All manuscripts are initially reviewed by the editorial staff, and if appropriate, will be assigned to a section editor. If the paper is judged to be suitable for possible publication, it will be sent to two or more external reviewers using our database of experts. All articles undergo this process with the following exceptions, which do not undergo our standard review process:

- **Letters to the Editor, Commentaries and Editorials** are based on the decision of the Editor, who may ask experts on the merit of their contents.
- **Practices Guidelines/Consensus Statements** - Special considerations may be made in this case as they are typically authored by experts in the field. The authors of the manuscript are asked to sign a form stating they have approved the manuscript and it is acceptable for publication. If they choose not to sign this, they must provide a list of five potential reviewers to review the manuscript, and the article will go through our standard peer review process. The Editors reserve the right to choose all reviewers and may not necessarily select reviewers from the list provided.
- **Meeting Reports** – based on the decision of the Editor.
- **Special Articles** – depending on the format and content, special articles may be solely based on the decision of the Editor, or undergo our standard review process.

Canada Post Publications Mail
Account Number: 40020215

Printed in Canada

ISSN (Print): 1198-0052
ISSN (Online): 1718-7729

CURRENT ONCOLOGY

A Canadian Cancer Research Journal

VOLUME 27, NUMBER 6, DECEMBER 2020

ORIGINAL ARTICLES

Medical Oncology

291 A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin

M.J. Raphael MD, M.D. Loughheed MD, X. Wei MSc, S. Karim MD, A.G. Robinson MD, P.L. Bedard MD, and C.M. Booth MD

300 A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma

S. Delos Santos BSc, S. Udayakumar BSc, A. Nguyen BSc, Y.J. Ko MD MSc, S. Berry MD MSc, M. Doherty MSc, and K.K.W. Chan MD MSc PhD

e527* Clinicopathologic characteristics, survival, and treatments for gastric adenocarcinoma: a population-based study

H.S. Li MD, X. Liu BN, M.Y. Zhang MD, K. Cheng MD, Y. Chen MD, Y.W. Zhou MD, and J.Y. Liu PhD

e537* Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis

E. Tai MD PhD, S. Kennedy MD, A. Farrell MLIS, A. Jaber MD, J. Kachura MD, and R. Beecroft MD

e547* Presenting stage and risk group in men dying of prostate cancer

S. Parimi MD, S. Bondy BSc, M. Aparicio BSc, K. Sunderland, J. Cho MD, F. Bachand MD, K. Nguyen Chi MD, T. Pickles MD, and S. Tyldesley MD

e552* Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment

B.C. Tse BSc, B.I. Said MD, Z.J. Fan BSc, K. Hueniken MPH, D. Patel BSc, G. Gill HSc, M. Liang BSc, M. Razooqi HSc, M.C. Brown MSc, A.G. Sacher MD, P.A. Bradbury MD, F.A. Shepherd MD, N.B. Leighl MD, W. Xu PhD, D. Howell PhD, G. Liu MD, and G. O'Kane MD

Surgical Oncology

e560* Lysine analogue use during cancer surgery: a survey from a Canadian tertiary care centre

J. Montroy MSc, B. Hutton PhD, D.A. Fergusson PhD, A. Tinmouth MD MSc, L.T. Lavallée MD MSc, I. Cagiannos MD, C. Morash MD, A. Flaman PhD, and R.H. Breau MD MSc

Medical Economics

307 The cost of failed first-line cancer treatment related to continued smoking in Canada

N. Iragorri MSc, B. Essue PhD, C. Timmings MPH, D. Keen MPA, H. Bryant MD PhD, and G.W. Warren MD

e569* Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact

K.M. Johnston PhD, B.S. Sheffield MD, S. Yip MD, P. Lakzadeh MSc, C. Qian MSc, and J. Nam MSc

e578* Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada

T. Younis MBBCh, A. Lee PhD, M.E. Coombes MSc, N. Bouganim MD, D. Becker MSc, C. Revil, and G.S. Jhuti

Rehabilitation and Survivorship

e590* Primary care use after cancer treatment: an analysis of linked administrative data

R. Urquhart PhD and L. Lethbridge MA

e596* Pre-transplant marital status and hematopoietic cell transplantation outcomes

J. Tay MD, S. Beattie PhD, C. Bredeson MD, R. Brazauskas PhD, N. He MS, I.A. Ahmed MD, M. Aljurf MD, M. Askar MD, Y. Atsuta MD, S. Badawy MD, A. Barata PhD, A.M. Beitinjaneh MD, N.S. Bhatt MD, D. Buchbinder MD, J. Cerny MD, S. Ciurea MD, A. D'Souza MD, J. Dalal MD, N. Farhadfar MD, C.O. Freytes MD, S. Ganguly MD, U. Gergis MD, S. Gerull MD, H.M. Lazarus MD, T. Hahn MD, S. Hong MD, Y. Inamoto MD, N. Khera MD, T. Kindwall-Keller MD, R.T. Kamble MD, J.M. Knight MD, Y.N. Koleva PhD, A. Kumar MD, J. Kwok MD PhD, H.S. Murthy MD, R.F. Olsson MD, M. Angel Diaz-Perez MD, D. Rizzieri MD, S. Seo MD, S. Chhabra MD, H. Schoemans MD, H.C. Schouten MD, A. Steinberg MD, K.M. Sullivan MD, J. Szer MD, D. Szwajcer MD, M.L. Ulrickson MD, L.F. Verdonck MD, B. Wirk MD, W.A. Wood MD, J.A. Yared MD, and W. Saber MD

Palliative Care

313 Perspectives of hematology oncology clinicians about integrating palliative care in oncology

R. Booker MN BScN, S. Dunn MPH, M.A. Earp PhD, A. Sinnarajah MD MPH, P.D. Biondo PhD, and J.E. Simon MB ChB

Oncology Education

e607* Code status communication training in postgraduate oncology programs: a needs assessment

O.H. Levine MD, S.K. Dhesy-Thind MD, M.M. McConnell PhD, M.C. Brouwers PhD, and S.D. Mukherjee MD

e614* Implementing changes to a residency program curriculum before competency-based medical education: a survey of Canadian medical oncology program directors

R. Arora MD, G. Kazemi MD, T. Hsu MD, O. Levine MD MSc, S.K. Basi MD, J.W. Henning MD, J. Sussman MD MSc, and S.D. Mukherjee MD MSc

PRACTICE GUIDELINES

321 Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer

P.K. Cheema MD MBiotech, M. Gomes MD PhD, S. Banerji MD, P. Joubert MD PhD, N.B. Leighl MMedSc MD, B. Melosky MD, B.S. Sheffield MD, T. Stockley PhD, and D.N. Ionescu MD

e621* Canadian guidelines on the management of colorectal peritoneal metastases

A. Brind'Amour MD, P. Dubé MD, J.F. Tremblay MD, M.L. Soucisse MD, L. Mack MD, A. Bouchard-Fortier MD, J.A. McCart MD, A. Govindarajan MD, D. Bischof MD, E. Haase MD, C. Giacomantonio MD, P. Hebbard MD, R. Younan MD, A MacNeill MD, C. Boulanger-Gobeil MD, and L. Sidéris MD

e632* First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma

S. Bhella MD, N.P. Varela PhD, A. Aw MD, C. Bredeson MD MSc, M. Cheung MD MSc, M. Crump MD, G. Fraser MD, S. Sajkowski, and T. Kouroukis MD MSc

REVIEW ARTICLES

e645* Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia

V. Banerji MD, A. Aw MD, S. Robinson MD, S. Doucette MSc, A. Christofides MSc RD, and L.H. Sehn MD

e656* Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis

J. Huang MD and X. Teng MD

CASE REPORT

330 The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review

D. Forner MD, P. Horwich MD, J.R. Trites MD, H. Hollenhorst MD, M. Bullock MD, and N.W.D. Lamond MD

SPECIAL ARTICLE

336 Cancer-related lymphedema: clinical pearls for providers

G. Chaput BA MD MA CAC(Pall Med), M. Ibrahim MSc PT, and A. Towers MD CAC(Pall Med)

ABSTRACTS

e664* Abstracts submitted to the Cell Therapy Transplant Canada 2020 Annual Conference

Cell Therapy Transplant Canada

* Full-text e-manuscript available at www.current-oncology.com